Intravenous DNase I for the Treatment of Sepsis (IDEALSepsisI)
Key facts
- Who runs it
- McMaster University
- Where
- Canada1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 36 people, planned
- Started
- 17 Jan 2023
- Planned end
- 30 Sept 2026
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Intravenous DNase I
- Record updated
- 3 March 2026
Who can take part
- Age
- 18 years to 100 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Age of ≥18 years
- Admitted to the ICU in the last 48 hours
- Suspected or proven infection as the admitting diagnosis
- A sequential (sepsis) organ function assessment (SOFA) score of ≥2 above baseline
- Expected to remain in the ICU for ≥ 72 hours
Who cannot take part
- Have a significant risk of bleeding as evidenced by one of the following:; Surgery requiring general or spinal anesthesia within 24 hours before enrolment; The potential need for surgery in the next 24 hours; Evidence of active bleeding; A history of severe head trauma requiring hospitalization; Intracranial surgery, or stroke within three months before the study; Any history of intracerebral arteriovenous malformation, cerebral aneurysm, or mass lesions of the central nervous system; A history of congenital bleeding diatheses; Gastrointestinal bleeding within five weeks before the study unless corrective surgery had been performed; Trauma is considered to increase the risk of bleeding; Presence of an epidural catheter; Need for therapeutic anticoagulation
- Receiving DNase I by inhalation
- Have other forms of clinically apparent shock, including cardiogenic, obstructive (massive pulmonary embolism, cardiac tamponade, tension pneumothorax), hemorrhagic, neurogenic, or anaphylactic shock
- Terminal illness with a life expectancy of fewer than three months
- No consent/inability to obtain consent from a substitute decision-maker
- Pregnant and/or breastfeeding
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Phase I dose-escalation safety and feasibility of IV DNase I in ICU septic patients.
The 2 groups in the trial
- Intravenous DNase ITreatment being tested
We will enroll up to 36 Participants; each is receiving repeated unit doses of DNase I, BID, delivered by IV infusion over 3 or 7 consecutive days (12 +/- 1 hour apart) according to the following dose-escalation schedule with up to 6 Participants per dose panel. * Panel 1: 25 µg/kg, BID for 3 days (cumulative dose: 150 µg/kg) * Panel 2: 25 µg/kg, BID for 7 days (cumulative dose: 350 µg/kg) * Panel 3: 125 µg/kg, BID for 3 days (cumulative dose: 750 µg/kg) * Panel 4: 125 µg/kg, BID for 7 days (cumulative dose: 1750 µg/kg)
- ControlNo study treatment, for comparison
We will also enroll 12 septic Participants who do not receive intravenous DNase I (as Comparator Group). These patients will be recruited contemporaneously based on the same inclusion and exclusion criteria.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Intravenous DNase I for the Treatment of Sepsis: A Phase I Safety and Feasibility Study in ICU Patients
- Criteria questions
- Built from NCT05453695, who can take part
- Publications
- Record updated
- 3 March 2026